Lung Cancer Trial, Recruiting (NCT05550961)

Lung Cancer Trial, Recruiting NCT05550961 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05550961 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older at the time of signing the consent form
People who have been diagnosed with lung cancer (either non-small cell or small cell type) at any stage (I through IV), confirmed through a tissue or cell sample
People who are being considered for, or have already been treated with, newer types of cancer treatments such as immunotherapy, targeted therapy, or next-generation therapies

Who may not be able to join:

People who are currently taking, or plan to take, other unapproved cancer treatments at the same time as this trial
People who have never received any form of innovative systemic (whole-body) cancer therapy
People whose only cancer treatment has been a local treatment such as surgery alone or radiotherapy alone
People who have only ever received standard chemotherapy, without any newer or innovative treatments
People whose cancer treatment was given before the year 2010

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carlo Genova, IRCCS Ospedale Policlinico San Martino, Genova

Phone: +390223903647

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05550961

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +390223903647

More information: https://clinicaltrials.gov/study/NCT05550961

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older at the time of signing the consent form
People who have been diagnosed with lung cancer (either non-small cell or small cell type) at any stage (I through IV), confirmed through a tissue or cell sample
People who are being considered for, or have already been treated with, newer types of cancer treatments such as immunotherapy, targeted therapy, or next-generation therapies

Who may not be able to join:

People who are currently taking, or plan to take, other unapproved cancer treatments at the same time as this trial
People who have never received any form of innovative systemic (whole-body) cancer therapy
People whose only cancer treatment has been a local treatment such as surgery alone or radiotherapy alone
People who have only ever received standard chemotherapy, without any newer or innovative treatments
People whose cancer treatment was given before the year 2010

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Registry

ClinicalTrials.gov

Start date

1 October 2022

Est. completion

1 October 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Response Rate; Progression-Free Survival; Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov